KCM
SMMT icon

Knoll Capital Management’s Summit Therapeutics SMMT Stock Holding History

Knoll Capital Management’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-91,800
Closed -$1.15M – 16
2017
Q3 		$1.15M Sell
91,800
-8,200
-8% -$106K 0.99% 10
2017
Q2 		$1.1M Hold
100,000
– – 1.46% 10
2017
Q1 		$1.33M Buy
+100,000
New +$1.16M 2% 9

Other funds holding SMMT

LPU
Lansdowne Partners (UK) London, United Kingdom $1.87B AUM 61.55% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
GPCM
Granite Point Capital Management Boston, Massachusetts $4.9M AUM 38.41% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Knoll Capital Management's SMMT Position: Q4 2017 in Review

Knoll Capital Management sold out of Summit Therapeutics (SMMT) in Q4 2017, closing a stake of 91,800 shares — an estimated $1.15M sold.

Knoll Capital Management first reported a position in SMMT in Q1 2017 and held it in 3 quarters. The position peaked at $1.33M in Q1 2017. 21 funds tracked by Wall St. Rank hold SMMT as of Q4 2017.

  • Knoll Capital Management reported no remaining Summit Therapeutics position as of Q4 2017 after selling out during the quarter.
  • Knoll Capital Management sold 91,800 Summit Therapeutics shares in Q4 2017, an estimated $1.15M.
  • Knoll Capital Management first reported a position in Summit Therapeutics in Q1 2017 and held it in 3 quarters.
  • Knoll Capital Management's Summit Therapeutics position peaked at $1.33M in Q1 2017.
  • 21 funds tracked by Wall St. Rank held Summit Therapeutics as of Q4 2017.

Based on Knoll Capital Management's 13F filing for Q4 2017, filed 14 Feb 2018.